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Dear editor
We read with great interest the recent study by Sun et al 1 published in Neuropsychiatric Disease and Treatment. Intracranial hypertension (ICH) remains the most common cause of death in patients with traumatic brain injury (TBI). 1 After the trauma, secondary injuries arise due to perfusion and molecular changes that begin after the moment of the trauma resulting from the interaction of intracerebral and extracerebral factors, which add to the neuronal injury. Hypotension, hypoglycemia, hypercapnia, respiratory hypoxia, anemic hypoxia, and electrolyte disturbances are the main factors associated with secondary injury, which can lead to ICH and cerebral hypoxia, thereby worsening the morbidity and death rates associated with brain injury. 1, 2 In this paper, the authors have discussed the multimodality intracranial monitoring carried out in 62 severe TBI patients, with evidence of hypothermia as a therapeutic strategy to adequately control intracranial pressure (ICP).
The study had well-established, rigid inclusion criteria to find adequate results, with early evaluation of patients subjected to screening for severe TBI and proper exclusion of systemic trauma.
It has already been established that adequate ICP management is important for the better outcome of severe TBI patients. 1 However, it is important to emphasize that patients with severe TBI need complex management. Appropriate investigation is always recommended; however, treating ICH alone may not be sufficient for neuronal preservation, as factors related to oxygen concentration in brain tissues have to be taken into account and also there is a possibility that a few treatments carried out to reduce ICP may cause side effects. 3−6 In this context, we agree that multimodality monitoring aims to safely demonstrate the type of individual therapy that benefits the brain environment at each phase of treatment in the intensive care unit. The most important aim is to adequately demonstrate the procedures that had a poor benefit−risk profile or that could even harm the brain. 7, 8 The paper has also provided us a didactic solid concept of the major benefits of mild hypothermia for patients with the neuroprotective concept in intensive care unit. The authors discussed hypothermia value for the microscopic neurotransmitter environment, vascular and neuronal metabolic aspect. However, some points need to be clarified by the authors. A wide age criterion ranging from 18 to 72 years can be a problem for analyzing the results. The authors also have not reported on which decompressive craniectomy-indicating protocol was used and what ICP limit was adopted.
Another point to be noted is the controversial discussion of the real role of hypothermia in TBI. Experimental studies on hypothermia have shown good results with a reduction in morbidity and mortality rates. 11, 12 However, although there is evidence regarding ICP control and improved perfusion pressure, improvements were not confirmed clinically in the late functional recovery of patients. 13 In this paper, the authors did not present patient outcomes, not even shortterm outcomes, which is perhaps the greatest limitation of the study. In clinical research, although the relevance of monitoring data is important, clinical status of patients is always the most important.
So, we tend to agree with the main conclusion of the study that multimodality intracranial monitoring has its value in the acute setting of severe TBI in the intensive care unit, but more studies are necessary to prove the probable benefits of this improvement for TBI patient care, with long-term outcomes assessment and trauma scales.
